Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women

@article{Lundkvist2005EconomicEO,
  title={Economic evaluation of parathyroid hormone (PTH) in the treatment of osteoporosis in postmenopausal women},
  author={Jonas Lundkvist and Olof Johnell and Cyrus Cooper and David P. Sykes},
  journal={Osteoporosis International},
  year={2005},
  volume={17},
  pages={201-211}
}
Parathyroid hormone (PTH) is a new treatment for osteoporosis and has been shown to reduce the risks of vertebral and non-vertebral fractures in postmenopausal women in clinical trials. The objective of this study was to estimate the cost-effectiveness of teriparatide in addition to calcium and vitamin D, using a simulation model. The base case analysis was conducted for a cohort of 69-year-old women in Sweden who had at least one previous vertebral fracture and low bone mineral density. The… CONTINUE READING